Trials / Terminated
TerminatedNCT00885547
Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis
Prospective Clinical Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis.
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Nanjing University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to: 1. To evaluate the latest effects of TW for IgA nephropathy (IgAN) with asymptomatic abnormal urinalysis. 2. To evaluate the safety and tolerability of TW.
Detailed description
Patients who fit the inclusion criteria will be randomly divided into three groups: TW group (TW at dosage of 90 mg/d), ARB group (the control group, valsartan at dosage of 160 mg/d) and combined treatment group (TW at dosage of 60 mg/d and valsartan at dosage of 80 mg/d).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tripterygium wilfordii (TW) | 90 mg/d for 6 months |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2011-04-01
- Completion
- 2011-05-01
- First posted
- 2009-04-22
- Last updated
- 2015-04-02
Source: ClinicalTrials.gov record NCT00885547. Inclusion in this directory is not an endorsement.